Vertex Stock Looks Expensive. Does It Get Cheaper Ahead?

For questions about this article or underlying research, email help@trefis.com.

Vertex Pharmaceuticals (VRTX) stock trades at 27.6 times earnings over the twelve months to June 30, 2026. This valuation relies on an adjusted profit figure that adds back stock-based pay after tax, though our data does not show whether analysts’ forecasts make the same add-back. That is a rich price for a drugmaker whose sales grew 10.2% in that time. A single year of profit provides a narrow base, however, and the price looks different two years out. So what are you paying for Vertex on the profit it is expected to earn next?

What Vertex Stock Costs On The Profit Still Ahead

Based on its October 22, 2026 close of $535.17, Vertex stock trades at 30.0 times the consensus forecast for fiscal 2026 earnings and 25.9 times the forecast for fiscal 2027. The stock therefore costs more on fiscal 2026 profit than the 27.6 times paid on the last twelve months of adjusted earnings. It costs less only on fiscal 2027 profit.

The forecast has Vertex earning $4.53 billion in adjusted net income in fiscal 2026, below the $4.74 billion of adjusted net income in fiscal 2025. Vertex reported $3.95 billion of net income that year. Fiscal 2027 represents the less certain year: the highest and lowest earnings per share estimates for that period sit 20.5% of the forecast apart.

How Much Vertex Has To Grow For That Price

For the fiscal 2027 price to hold, Vertex has to grow sales to $14.7 billion. That target sits 10.7% above the consensus forecast for fiscal 2026, closely matching the growth pace the company delivered over its last twelve months. The forecast’s fiscal 2026 sales of about $13.3 billion also sit just above the top of management’s guide of $13.1 billion to $13.2 billion, which the company raised on August 3, 2026.

Vertex does not need margins above what it has earned before. In the consensus forecast, the net margin is 34.2% in fiscal 2026 and 35.7% in fiscal 2027. Both figures sit below the 39.6% adjusted net margin Vertex earned in fiscal 2025. Fiscal 2027 still needs a wider margin than fiscal 2026, however: net income is forecast to rise 15.6% on sales growth of 10.7%.

Where Could Vertex Fall Short Of The Forecast?

The likeliest gap is in where the growth comes from. TRIKAFTA/KAFTRIO made up 85.9% of Vertex’s fiscal 2025 revenue and grew just 0.724% that year. As a result, the forecast’s sales growth has to come mostly from ALYFTREK and the newer medicines. Those newer medicines are still small. In fiscal Q2 2026, CASGEVY brought in $76 million, and JOURNAVX generated $50 million. On the August 3 call, management said CASGEVY revenue will keep swinging from quarter to quarter with the timing of patient infusions. If the newer medicines grow more slowly, the forecast’s sales figure would come down.

Profit is the other area where the forecast could slip. Management said costs from product mix and manufacturing investments would be heavier on gross margin in the second half of 2026 than in the first. The company’s August guidance also left out the purchase of Crinetics, which Vertex agreed to buy for about $8.8 billion net of cash acquired. Vertex said then that it expected the deal to close in the third quarter, with a relatively modest effect on 2026 revenue and non-GAAP operating expenses, and to add to non-GAAP operating income starting in 2029. The deal closed on September 1, 2026. Either item could weigh on profit.

If Vertex earns what analysts forecast, the prices on fiscal 2026 and fiscal 2027 profit are a fair picture of what you pay for Vertex. Where it is most likely to fall short is in the newer medicines and in the cost of the Crinetics deal. A shortfall there would make the stock a riskier bet at 25.9 times fiscal 2027 profit that Vertex has not yet earned. Vertex is expected to report its third-quarter results in November. Revenue from CASGEVY and JOURNAVX is the measure to watch.

How To Act On VRTX?

Not necessarily on Vertex Pharmaceuticals alone, if your goal is long-term wealth. Wealth is built by owning the companies that keep outperforming, the leaders of their industries, wherever they are. Vertex Pharmaceuticals is one. Over the five years to October 2026, its stock rose 192%, ahead of 334 of the 363 other companies in Biotechnology, where the typical company fell 81%.

Finding companies like these takes comparison across industries and sectors, and that is what the Trefis High Quality (HQ) Portfolio does. It holds 30 quality companies in equal weight and, since its inception in September 2020, has returned more than 105%, ahead of a benchmark that combines the S&P 500, S&P Mid-cap and Russell 2000. See how we find the leaders.

Spot an error or want more like this? Tell us in 10 seconds.